Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 2Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Rituximab 130Cyclophosphamide 41Bendamustine Hydrochloride 39venetoclax 25fludarabine 25obinutuzumab 24Lenalidomide 23ibrutinib 22Gemcitabine 22Vincristine 20Prednisone 20tositumomab I-131 19Doxorubicin 19plerixafor 14Dexamethasone 14Granulocyte Colony-Stimulating Factor 12pirtobrutinib 11Brentuximab Vedotin 11glofitamab 10tocilizumab 9pembrolizumab 9ibritumomab tiuxetan 9Etoposide 9Azacitidine 9polatuzumab vedotin 8parsaclisib 8copanlisib 8acalabrutinib 8Drug Therapy 8ublituximab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Non-Hodgkin × cirmtuzumab × Clear all
NCT05431179 2023-04-21

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Oncternal Therapeutics, Inc

Phase 3 Withdrawn
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡